March 14, 2023 — 09:00 am EDT

      Written by
                        RTTNews.com for                             
        




RTTNews ->


(RTTNews) - AcelRx Pharmaceuticals, Inc. (ACRX) announced the divestment of its FDA-approved drug, DSUVIA to Alora Pharmaceuticals. The agreement provides AcelRx with a 15% royalty on commercial sales of DSUVIA, a 75% royalty on sales of DSUVIA to the Department of Defense, DSUVIA's single largest customer, and up to $116.5 million in sales-based milestones.  
AcelRx Pharma said the divestment will allow for AcelRx to focus its operations and capital on its late stage, high-value asset programs, with specific prioritization of its lead nafamostat program, Niyad.
For More Such Health News, visit rttnews.com. 
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

© 2023, Nasdaq, Inc. All Rights Reserved.










To add symbols:


These symbols will be available throughout the site during your session.
To add symbols:


These symbols will be available throughout the site during your session.